Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the ...

Regeneron and GlaxoSmithKline have joined forces to generate genetic sequence data from the 500,000 volunteers in the UK’s Biobank database. The companies hope the initiative will give insights ...

On the basis of its industry-leading capabilities, Regeneron Genetics Center was selected by UK BioBank consortium members to complete proteomic assay data generation for the recently announced UK ...

Regeneron invested $119.5 million in Truveta ... than 10 times the scale of other health care databases, such as the UK Biobank, which includes 500,000 participants recruited between 2006 ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Regeneron pledged $119.5m while Illumina is ... interplay between genetics and health in unprecedented detail.” The UK Biobank, which holds genetic and health information from 500,000 ...